Search Result
Results for "
carbonic anhydrases
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
10
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-142849
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
|
-
-
- HY-161686
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 24 (Compound 11) is a human carbonic anhydrase (carbonic anhydrase) inhibitor. Ki values of Carbonic anhydrase inhibitor 24 for hCAs IX and XII were 10.7 and 7.5 nM, respectively .
|
-
-
- HY-137966A
-
|
AL-8520 oxalate
|
Carbonic Anhydrase
|
Cancer
|
|
N-Desethyl Brinzolamide oxalate is a dual inhibitor of Carbonic anhydrase II and Carbonic anhydrase IV with IC50s of 1.28 and 128 nM, respectively .
|
-
-
- HY-137364
-
|
|
Carbonic Anhydrase
|
Cardiovascular Disease
Metabolic Disease
|
|
Disulfamide, an orally active diuretic, is a carbonic anhydrase inhibitor with the IC50 value of 0.07 μM. Disulfamide leads to diuresis by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule .
|
-
-
- HY-19213A
-
-
-
- HY-19213
-
-
-
- HY-161286
-
-
-
- HY-142853
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
|
-
-
- HY-126117
-
|
|
Fungal
Carbonic Anhydrase
|
Infection
|
|
(+)-Xylariamide A (compound 6b) is a mycobacterial and fungal carbonic anhydrase probe with inhibitory activity against pathogen β-carbonic anhydrases .
|
-
-
- HY-144376
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 4 is carbonic anhydrase photoprobe/inhibitor. Carbonic anhydrase inhibitor 4 is against human carbonic anhydrases (hCA I-XIV) with Ki values of 640-1166 nM .
|
-
-
- HY-132156
-
|
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Carbonic anhydrase inhibitor 22 (Compd 2g), a sulfonamide carbonic anhydrase inhibitor, with Ki values of 762 nM (hCA I), 20.3 nM (hCA II), 8.3 nM (hCA VII), 17.9 nM (hCA IX) and 10.5 nM (hCA XII), repectively .
|
-
-
- HY-161028
-
|
|
Carbonic Anhydrase
Bacterial
|
Infection
|
|
Antibacterial agent 167 (compound 13) is an inhibitor of pathogenic bacterial carbonic anhydrases. Antibacterial agent 167 inhibits the growth of N. gonorrhea strains at concentrations ranging from 16 to 64 µg/mL .
|
-
-
- HY-147956
-
-
-
- HY-125375
-
-
-
- HY-W013316
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Lasamide is a potent human Carbonic Anhydrase inhibitor with Ki values of 7.54 and 2.76 nM for hCAXII and hCAIX, respectively .
|
-
-
- HY-106332A
-
|
MK 417
|
Carbonic Anhydrase
|
Endocrinology
|
|
Sezolamide hydrochloride (MK 417) is a potent topical carbonic anhydrase inhibitor. Sezolamide hydrochloride can be used in studies to reduce intraocular pressure .
|
-
-
- HY-146982
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-1 (compound 7f) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 1.2 and 113.6 nM, respectively. hCAII-IN-1 has the potential for the research of cancer diseases .
|
-
-
- HY-146983
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases .
|
-
-
- HY-163109
-
|
|
Carbonic Anhydrase
|
Infection
|
|
Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (Ki: 28.5 nM, 2.2 nM) .
|
-
-
- HY-101087
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Benzenesulphonamide (compound 1) is a potent carbonic anhydrase inhibitor. Benzenesulphonamide shows CA II inhibitory activity .
|
-
-
- HY-144639
-
-
-
- HY-158372
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA I-IN-3 (compound 24), an aryl ether derivative, is a potent carbonic anhydrase inhibitor. hCA I-IN-3 can inhibit carbonic anhydrase hCA I and hCA II isoenzymes, with IC50 values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 can be used for cancer research .
|
-
-
- HY-159568
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX-IN-22 is a highly selective inhibitor of human carbonic anhydrase (hCA) isoform XII (Ki=9.7 nM) with anticancer activity .
|
-
-
- HY-B0397A
-
|
Diclofenamide disodium
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Dichlorphenamide (Diclofenamide) disodium is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
|
-
-
- HY-169162
-
|
|
Carbonic Anhydrase
Cholinesterase (ChE)
|
Neurological Disease
|
|
hBChE-IN-3 (compound 30) is a combination of carbonic anhydrase (CA) activator and cholinesterase (ChE) inhibitor with IC50 values of 7.4 and 1.9 nM for AchE and BchE, respectively. hBChE-IN-3 can be used in the study of neurodegeneration and psychiatric disorders .
|
-
-
- HY-146207
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
HCAIX-IN-2 (compound 9d) is a selective carbonic anhydrase inhibitor with the Ki values of 24.6 nM and 45.3 nM for hCA IX and hCA XII, respectively .
|
-
-
- HY-132155
-
|
NSC 91508
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Indan-5-sulphonamide (Compd 1) is a carbonic anhydrase inhibitor and anticonvulsant agent, with Ki values of 0.039 nM (hCA XII), 6.5 nM (hCA XIV) and 5.1 nM (hCA XIV), respectively .
|
-
-
- HY-115999
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 12 is a potent CA II inhibitor, also has inhibitory activity in CA I (Kis of 1.72 and 271 nM in CA II and CA I, respectively). Carbonic anhydrase inhibitor 12 has potent anticancer activity against different cancer cell lines .
|
-
-
- HY-157462
-
|
|
Carbonic Anhydrase
|
Infection
|
|
FC14-584B, a dithiocarbamate, is a β-Carbonic Anhydrase inhibitor. FC14-584B inhibits the growth of trophozoites. FC14-584B can be used for the research of tuberculosis .
|
-
-
- HY-119063
-
|
|
Carbonic Anhydrase
|
Others
|
|
L-645151 is a carbonic anhydrase inhibitor with ocular penetration and hypotensive activity. L-645151 lowers the elevated intraocular pressure (IOP) of o-chymotripsinized (o-CT) rabbit eyes. L-645151 is promising for research of an ocular hypotensive agent .
|
-
-
- HY-D2345
-
|
|
Fluorescent Dye
Carbonic Anhydrase
|
Cancer
|
|
GZ22-4 is a near-infrared (NIR) fluorescent probe. GZ22-4 shows high affinity for carbonic anhydrase IX (CAIX), with a Kd of 0.2 nM. GZ22-4 can be used for the research of visualize CAIX-positive tumors .
|
-
-
- HY-147828
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX-IN-11 (Compound 5d) is a selective carbonic anhydrase IX and XII inhibitor with Ki s of 32.7 and 623.5 nM for hCA IX and hCA XII, respectively. hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
|
-
-
- HY-147827
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX-IN-10 (Compound 6i) is a selective carbonic anhydrase IX and XII inhibitor with Ki s of 61.5 and 586.8 nM for hCA IX and hCA XII, respectively. hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
|
-
-
- HY-B1386
-
|
|
Bacterial
Carbonic Anhydrase
Sodium Channel
|
Infection
|
|
Halazone is an atypical antimicrobial sulfonamide derivative and a carbonic anhydrase II inhibitor with a Kd value of 1.45 µM. Halazone protects sodium channels from inactivation. Halazone is widely used for disinfection of drinking water .
|
-
-
- HY-144264
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
hCAII-IN-6 (Compound S-13) is a potent human carbonic anhydrase II (hCA II) inhibitor with a Ki of 4.4 nM. hCAII-IN-6 also inhibits other hCAs isoforms I, IV and IX, with Ki values of 9.2 nM, 480.2 nM and 14.7 nM, respectively. hCAII-IN-6 can be used for glaucoma research .
|
-
-
- HY-150573
-
|
|
CDK
Carbonic Anhydrase
|
Cancer
|
|
CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
|
-
-
- HY-77036
-
Furagin
1 Publications Verification
Furazidine; Furazidin
|
Antibiotic
Bacterial
Carbonic Anhydrase
|
Infection
Cancer
|
|
Furagin (Furazidine), an analogue of Nitrofurantoin (HY-A0090), is an antibiotic with antibacterial activity against ESKAPE pathogens with MIC values of 0-32 µg/mL. Furagin inhibits human Carbonic anhydrases . Furagin is promising for research of cancer and urinary tract infections (UTIs) .
|
-
-
- HY-B0588A
-
|
AL-4862 hydrochloride
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
|
-
-
- HY-B0588
-
|
AL-4862
|
Carbonic Anhydrase
|
Others
Neurological Disease
|
|
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
|
-
-
- HY-W008343
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .
|
-
-
- HY-161507
-
|
|
Carbonic Anhydrase
Cholinesterase (ChE)
|
Metabolic Disease
|
|
hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). . .
|
-
-
- HY-147955
-
|
|
Carbonic Anhydrase
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
|
hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
|
-
-
- HY-149498
-
-
-
- HY-163753
-
|
|
Carbonic Anhydrase
|
Others
|
|
Carbonic anhydrase inhibitor 25 (compound 6a) is a potent carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 25 shows inhibition for hCA I and hCA II receptor .
|
-
-
- HY-161374
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonic anhydrase (Carbonic Anhydrase). The Ki of Carbonic anhydrase inhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively .
|
-
-
- HY-P1775A
-
|
|
Carbonic Anhydrase
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Carbonic anhydrase isoenzyme is the isoenzyme of Carbonic anhydrase (HY-P1775). Carbonic anhydrase isoenzyme is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase isoenzyme catalyzes reversible conversion of carbon dioxide to bicarbonate and protons, and can be used for the research of cancer, glaucoma, obesity and epilepsy .
|
-
-
- HY-147954
-
|
|
Carbonic Anhydrase
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
|
α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonic anhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
|
-
-
- HY-115998
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 11 (compound VI) is a potent, selective carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 11 shows Ki values of 40, 39, 200 and 900 nM against CA II, IX, and XII, respectively .
|
-
-
- HY-158078
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 21 (Compound 5h) is a selective carbonic anhydrase (hCA IX) inhibitor, with a Ki of 15.1 nM, and is highly selective against other investigated isoform. Carbonic anhydrase inhibitor 21 can be used for anticancer research .
|
-
-
- HY-P1775
-
|
EC 4.2.1.1
|
Carbonic Anhydrase
|
Neurological Disease
Metabolic Disease
Cancer
|
Carbonic anhydrase, Bovine erythrocytes (EC 4.2.1.1) is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy .
|
-
- HY-161174
-
-
- HY-150570
-
|
|
Carbonic Anhydrase
CDK
|
Cancer
|
|
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .
|
-
- HY-151472
-
|
|
Carbonic Anhydrase
|
Infection
|
|
hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .
|
-
- HY-144807
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 9 is a potent carbonic anhydrase (CA) inhibitor with Kis of 56.4 and 56.9 nM for hCA II and IX, respectively. Antiproliferative activity .
|
-
- HY-115994
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 10 is a potent hCA IX inhibitor with a Ki value of 6.2 nM. Carbonic anhydrase inhibitor 10 exhibits anti-proliferative activity against MCF-7 cancer cell line with an IC50 of 11.9 μM. Carbonic anhydrase inhibitor 10 can be used for cancer research .
|
-
- HY-163268
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 18 (Compound 9) is a human carbonic anhydrase (hCA) isoform inhibitor, with Kis of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 18 can be used for the research of cancer .
|
-
- HY-163660
-
|
|
Carbonic Anhydrase
|
Infection
|
|
Carbonic anhydrase inhibitor 23 (compound 40) is a potent inhibitor of carbonic anhydrase (CA), with the Ki of 617.2 nM and 434.1 nM for hCA I (α) and hCA II (α), respectively .
|
-
- HY-B1480
-
-
- HY-151916
-
|
|
Apoptosis
Carbonic Anhydrase
Phosphodiesterase (PDE)
|
Cancer
|
|
Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis .
|
-
- HY-151917
-
|
|
Apoptosis
Carbonic Anhydrase
Phosphodiesterase (PDE)
|
Cancer
|
|
Enpp/Carbonic anhydrase-IN-2 (compound 1i) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.13, 1.07, 0.74, 0.33, 0.68 for NPP1, NPP2, NPP3, CA-IX, CA-XII respectively. Enpp/Carbonic anhydrase-IN-2 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-2 induces Apoptosis .
|
-
- HY-157139
-
|
|
Carbonic Anhydrase
Phosphatase
|
Inflammation/Immunology
|
|
ALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonic anhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
|
-
- HY-161142
-
-
- HY-161143
-
-
- HY-B2147
-
-
- HY-N0085
-
|
6,7,8-Trimethoxycoumarin; Fraxetin dimethyl ether
|
Carbonic Anhydrase
|
Cancer
|
|
Dimethylfraxetin is a Carbonic anhydrase inhibitor, with a Ki value of 0.0097 μM.
|
-
- HY-108316
-
-
- HY-B0553
-
|
L584601
|
Carbonic Anhydrase
|
Inflammation/Immunology
Cancer
|
|
Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
|
-
- HY-162226
-
|
|
Carbonic Anhydrase
|
Others
|
|
Carbonic anhydrase inhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonic anhydrase inhibitor 19 reveals an intraocular pressure (IOP) lowering effect .
|
-
- HY-144641
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
|
-
- HY-144640
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
|
-
- HY-146010
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 13 (compound 7) is a potent carbonic anhydrase (CA) inhibitor, which features 3-methylthiazolo[3,2-a]benzimidazole moiety (as a tail) connected to the zinc anchoring benzenesulfonamide moiety via ureido linker .
|
-
- HY-B0483
-
-
- HY-W403930
-
-
- HY-119919
-
-
- HY-151493
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAII-IN-1 (compound 3n), a thiosemicarbazide derivative, is a potent, selective carbonic anhydrase-II (CA-II) inhibitor with an IC50 value of 10.3 µM for bovine CA-II. CAII-IN-1 can be used in research of carbonic anhydrase related biological disorders .
|
-
- HY-151494
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAII-IN-2 (compound 3g), a thiosemicarbazide derivative, is a potent, selective carbonic anhydrase-II (CA-II) inhibitor with an IC50 value of 12.1 µM for bovine CA-II. CAII-IN-2 can be used in research of carbonic anhydrase related biological disorders .
|
-
- HY-B0553S
-
|
L584601-d6
|
Isotope-Labeled Compounds
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].
|
-
- HY-129986
-
|
|
Others
|
Others
|
|
hCAI/II-IN-9 is a carbonic anhydrase inhibitor with inhibitory activity against human carbonic anhydrase isoforms I, II, IX, and XII. The inhibition constants (Ki) of hCAI/II-IN-9 for hCA I are in the range of 7.9-894 nM, for hCA II are in the range of 7.5-1645 nM, for hCA IX are in the range of 5.0-240 nM, and for hCA XII are in the range of 0.47-2.83 nM. hCAI/II-IN-9 may have potential applications in inhibiting a variety of pathologies involving these carbonic anhydrase isoforms .
|
-
- HY-B0782S
-
-
- HY-B0553R
-
|
|
Carbonic Anhydrase
|
Inflammation/Immunology
Cancer
|
|
Methazolamide (Standard) is the analytical standard of Methazolamide. This product is intended for research and analytical applications. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
|
-
- HY-156013
-
-
- HY-146257
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX/XII-IN-2 (compound 6a) is a potent and selective hCAIX and hCAXIIinhibitor with Ki values of >10000, >10000, 30.0, 3.6 nM for hCAI, hCAII, hCAIX and hCAXII, respectively .
|
-
- HY-146258
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX/XII-IN-3 (compound 6q) is a potent and selective hCAIX and hCAXIIinhibitor with Ki values of >10000, >10000, 66.2, 4.4 nM for hCAI, hCAII, hCAIX and hCAXII, respectively .
|
-
- HY-146256
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAXII-IN-5 (compound 6o) is a potent and selective hCAXII inhibitor with Ki values of >10000, >10000, 286.1, 1.0 nM for hCAI, hCAII, hCAIX and hCAXII, respectively .
|
-
- HY-147984
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAXII-IN-3 (Compound 6o) is a selective human carbonic anhydrase XII (hCAXII) inhibitor with a Ki of 10.0 nM .
|
-
- HY-147353
-
|
|
Carbonic Anhydrase
|
Others
|
|
Phenylsulfamide (Compound 10) is a human carbonic anhydrase-II (hCA-II) inhibitor with a Kd of 45.50 μM and a Ki of 79.60 μM .
|
-
- HY-B1364
-
-
- HY-108316S
-
-
- HY-B0588S
-
|
AL-4862-d5
|
Carbonic Anhydrase
|
Others
|
|
Brinzolamide-d5 is the deuterium labeled Brinzolamide. Brinzolamide (AL 4862) is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.
|
-
- HY-108316R
-
|
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Sultiame (Standard) is the analytical standard of Sultiame. This product is intended for research and analytical applications. Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
|
-
- HY-152140
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II .
|
-
- HY-W011293
-
|
2,4-Disulfamyl-5-trifluoromethylaniline
|
Phosphodiesterase (PDE)
|
Others
|
|
DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase .
|
-
- HY-B0483R
-
|
|
Carbonic Anhydrase
|
Metabolic Disease
|
|
Tioxolone (Standard) is the analytical standard of Tioxolone. This product is intended for research and analytical applications. Tioxolone is an inhibitor of the metalloenzyme carbonic anhydrase I and has anti-acne activity.
|
-
- HY-147952
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
Inflammation/Immunology
|
|
AChE-IN-20 (compound M26) is a potent AChE inhibitor with IC50 value of 397.32 nM and with Ki value of 335.76 nM. AChE-IN-20 shows inhibition potency against hCA I , hCA II and α-GLY with IC50 values of 84.14, 69.24 and 52.08 nM and with Ki values of 97.86, 76.23 and 57.93 nM, respectively .
|
-
- HY-B0782
-
-
- HY-B0782A
-
-
- HY-151495
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAII-IN-3 (compound 3h), a thiosemicarbazones derivatives, is a potent carbonic anhydrase-II (CA-II) inhibitor with an IC50 value of 13.4 µM .
|
-
- HY-W424792A
-
-
- HY-P99023
-
|
G250; cG250
|
Carbonic Anhydrase
|
Cancer
|
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
|
-
- HY-B0397
-
|
Diclofenamide
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
|
-
- HY-120677
-
|
|
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
AHR-15010 is an oral active carbonic anhydrase inhibitor with the IC50 of 0.13 μM. AHR-15010 shows anti-arthritic activity and can be used for study of arthritis .
|
-
- HY-157321
-
|
|
Carbonic Anhydrase
|
Neurological Disease
|
|
hCAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively .
|
-
- HY-149011
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CA IX-IN-1 (compound 12g) is an effective and selective inhibitor of hCA IX with IC50 value of 7 nM. CA IX-IN-1 exhibits antitumor activity .
|
-
- HY-149402
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA XII-IN-6 (compound 4d) is a potent hCA XII inhibitor with a Ki value of 84.2 nM. hCA XII-IN-6 has anti-proliferative activity. hCA XII-IN-6 can be used in research of cancer .
|
-
- HY-155271
-
|
|
Carbonic Anhydrase
|
Others
|
|
hCAXII-IN-7 (compound 6e) is a hCA XII inhibitor. hCAXII-IN-7 has BBB permeability. hCAXII-IN-7 induces 786-0, SF-539 and HS 578 T cells apoptotic .
|
-
- HY-B0109A
-
|
L671152 hydrochloride; MK507 hydrochloride
|
Carbonic Anhydrase
|
Cardiovascular Disease
Others
|
Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
|
-
- HY-B0109
-
|
L671152; MK507
|
Carbonic Anhydrase
|
Cancer
|
Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
|
-
- HY-B0242
-
|
Sulphanilamide
|
Bacterial
Antibiotic
|
Infection
|
|
ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonic anhydrase inhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum .
|
-
- HY-B1056
-
|
Propazol; 2-Benzimidazolepropionic acid
|
Bacterial
Parasite
Antibiotic
Carbonic Anhydrase
|
Infection
Cancer
|
|
Procodazole is an orally active enhancer and a non-specific active immune protector against viral and bacterial infections. Procodazole also exhibits antiparasitic activity. In addition, Procodazole is a carbonic anhydrase inhibitor with antitumor activity .
|
-
- HY-161697
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX-IN-20 (compound APBS-5m) is a potent inhibitor of carbonic anhydrase IX (hCA IX), with the Ki of 2.7 nM. hCAIX-IN-20 plays an important role in cancer research .
|
-
- HY-163116
-
|
|
COX
Carbonic Anhydrase
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonic anhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII) .
|
-
- HY-163117
-
|
|
COX
Carbonic Anhydrase
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonic anhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII) .
|
-
- HY-144268
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-7 (Compound R-13) is a potent human carbonic anhydrase (hCA) inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively .
|
-
- HY-113719
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
VM4-037 can be used for the synthesis of VM4-037(18F). VM4-037(18F) is a fluorinated PET imaging agent for carbonic anhydrase IX .
|
-
- HY-162063
-
-
- HY-32933
-
|
|
Carbonic Anhydrase
|
Metabolic Disease
|
|
4-Acetylphenylboronic acid is a potent inhibitor of carbonic anhydrases II(CA II), with IC50s of 246 μM and 281.40 μM for bovine CA II (bCA II) and human CA II (hCA II), respectively .
|
-
- HY-B0782S1
-
-
- HY-146385
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA I/II) inhibitor with IC50 values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively .
|
-
- HY-149301
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX-IN-18 (compound 30) is an inhibitor of carbonic anhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research .
|
-
- HY-B0782R
-
|
|
Carbonic Anhydrase
Autophagy
Bacterial
|
Cardiovascular Disease
Cancer
|
|
Acetazolamide (Standard) is the analytical standard of Acetazolamide. This product is intended for research and analytical applications. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
|
-
- HY-146355
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonic anhydrase (hCA) inhibitor with Ki values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .
|
-
- HY-147985
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
|
-
- HY-147986
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
|
-
- HY-146259
-
|
|
Carbonic Anhydrase
|
Others
|
|
hCAIX/XII-IN-4 (compound 6c) is a potent CAIX/XII inhibitor with the Ki values of 4.5 nM, 23.6 nM, >10000 nM and >10000 nM for CAXII, CAIX, CAI and CAⅡ, respectively .
|
-
- HY-149329
-
|
|
Carbonic Anhydrase
|
Neurological Disease
Cancer
|
|
hCAIX/VII-IN-1 is a selective hCA VII/IX inhibitor. hCAIX/VII-IN-1 inhibit hCAⅠ, hCAⅡ, hCAⅣ, hCAⅦ and hCAⅨ with Ki values of 336.2 nM,185.8 nM, 1055 nM, 35.6 nM and 28.0 nM, respectively. hCAIX/VII-IN-1 can be used for the research of cancer and neurological diseases .
|
-
- HY-123365
-
|
|
Others
|
Cancer
|
|
GV2-20 is a potent inhibitor ofcarbonic anhydrase 2.GV2-20shows antiproliferative effects in CML cell .
|
-
- HY-163710
-
|
|
VEGFR
Carbonic Anhydrase
|
Cancer
|
|
hCA/VEGFR-2 IN-5 (compound 9) is an indolone-phenylsulfonamide and a potential dual inhibitor of cancer-related hCA IX/XII and VEGFR-2. The IC50 values of hCA/VEGFR-2-IN-5 for VEGFR-2, hCA IX and hCA XII are 0.38 μM, 40 and 3.2 nM, respectively. hCA/VEGFR-2-IN-5 has antitumor activity .
|
-
- HY-13513
-
U-104
5 Publications Verification
SLC-0111
|
Carbonic Anhydrase
|
Cancer
|
|
U-104 (SLC-0111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model .
|
-
- HY-B1424
-
|
|
Carbonic Anhydrase
|
Cardiovascular Disease
Cancer
|
|
Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells .
|
-
- HY-147829
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAXII-IN-2 (compound 5i) is a potent human carbonic anhydrase XII (hCA XII) and hCA IX inhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .
|
-
- HY-161295
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX/XII-IN-10 (compound DK-8) is a carbonic anhydrase inhibitor. hCAIX/XII-IN-10 has potent inhibitory activity against tumor-associated membrane-bound isoforms hCA IX and XII, with Ki values of 32.5 nM and 29.2 nM .
|
-
- HY-B0397R
-
|
Diclofenamide (Standard)
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Dichlorphenamide (Standard) is the analytical standard of Dichlorphenamide. This product is intended for research and analytical applications. Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
|
-
- HY-120367
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
DTP348 is an inhibitor for carbonic anhydrase IX with a Ki of 8.3 nM in vitro and an IC50 of 19.26 μM in Xenopus oocytes. DTP348 exhibits slight toxicity in zebrafish embryos with LD50 of 3.5 mM. DTP348 can be used in the anti-cancer research .
|
-
- HY-155887
-
|
DSPE-PEG-NH2, MW 3400 ammonium
|
Liposome
|
Others
|
|
DSPE-PEG-Amine, MW 3400 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 3400 (ammonium) can be converted to aromatic aldehydes by reacting with acetone-protected aromatic hydrazines on the surface of bovine carbonic anhydrase (BCA) molecules. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-155908
-
|
DSPE-PEG-NH2, MW 10000 ammonium
|
Liposome
|
Others
|
|
DSPE-PEG-Amine, MW 10000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 10000 (ammonium) can be converted into aromatic aldehydes by reacting with acetone-protected aromatic hydrazines on the surface of bovine carbonic anhydrase (BCA) molecules. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-16726
-
|
CG100649
|
COX
Carbonic Anhydrase
|
Cancer
|
|
Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .
|
-
- HY-152141
-
|
|
Carbonic Anhydrase
|
Others
|
|
hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability .
|
-
- HY-155907
-
|
DSPE-PEG-NH2, MW 5000 ammonium
|
Liposome
|
Others
|
|
DSPE-PEG-Amine, MW 5000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. DSPE-PEG-Amine, MW 5000 (ammonium) amino group can be converted to aromatic aldehydes that react with acetone-protected aromatic hydrazides on the surface of the bovine carbonic anhydrase (BCA) molecule. Liposomes produce liposome-Bah-BCA conjugates by forming diaryl hydrazone (BAH) with target enzyme molecules. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-W440823A
-
|
DSPE-PEG-NH2, MW 1000 ammonium
|
Liposome
|
Others
|
|
DSPE-PEG-Amine, MW 1000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 1000 (ammonium) can be converted to an aromatic aldehyde, which reacts with an acetone-protected aromatic hydrazine on the surface of the bovine carbonic anhydrase (BCA) molecule. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-B0109S
-
|
|
Isotope-Labeled Compounds
Carbonic Anhydrase
|
Cancer
|
|
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
|
-
- HY-12155
-
|
|
Sodium Channel
Calcium Channel
|
Neurological Disease
|
|
JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na + channels and N-type Ca 2+ channels, but has a very weak inhibitory effect on human carbonic anhydrase-II (IC50 = 110 μM) .
|
-
- HY-118467
-
|
CL11366
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
|
-
- HY-146008
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAII-IN-3 (Compound 16) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity .
|
-
- HY-B0109AR
-
|
L671152 hydrochloride(Standard); MK507 hydrochloride (Standard)
|
Carbonic Anhydrase
|
Others
|
Dorzolamide (hydrochloride) (Standard) is the analytical standard of Dorzolamide (hydrochloride). This product is intended for research and analytical applications. Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
|
-
- HY-77036R
-
|
|
Antibiotic
Bacterial
Carbonic Anhydrase
|
Infection
Cancer
|
Furagin (Standard) is the analytical standard of Furagin. This product is intended for research and analytical applications. Furagin (Furazidine) is an analogue of Nitrofurantoin (HY-A0090) and has antibacterial activity. Furagin also inhibits human carbonic anhydrases (Kis: 260 and 57 nM for hCA IX and XII, respectively) .
|
-
- HY-B0242R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Sulfanilamide (Standard) is the analytical standard of Sulfanilamide. This product is intended for research and analytical applications. ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonic anhydrase inhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum .
|
-
- HY-B0122
-
-
- HY-B0109AS
-
|
L671152-d3 hydrochloride; MK507-d3 hydrochloride
|
Carbonic Anhydrase
Isotope-Labeled Compounds
|
Others
|
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
|
-
- HY-147922
-
|
|
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .
|
-
- HY-147923
-
|
|
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
hCAI/II-IN-3 (compound 5b) is a potent dual hCA I/II inhibitor with Ki values of 51.25, 13.15 and 42.18 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-3 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .
|
-
- HY-B1471
-
|
|
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
|
-
- HY-146007
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA IX-IN-1 (Compound 6f) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .
|
-
- HY-B0122A
-
|
McN 4853 lithium; RWJ 17021 lithium
|
iGluR
GABA Receptor
Sodium Channel
Calcium Channel
Potassium Channel
Carbonic Anhydrase
|
Neurological Disease
|
|
Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
|
-
- HY-163380
-
|
|
Carbonic Anhydrase
|
Neurological Disease
|
|
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .
|
-
- HY-W074975
-
|
5-Amino-1,3,4-thiadiazole-2-sulfonamide
|
Carbonic Anhydrase
|
Cancer
|
|
CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonic anhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .
|
-
- HY-B0124S
-
|
|
Carbonic Anhydrase
Calcium Channel
Sodium Channel
|
Neurological Disease
|
|
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
|
-
- HY-147799
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonic anhydrase (hCA) inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .
|
-
- HY-B0588AS
-
|
AL-4862-d5 hydrochloride
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
|
-
- HY-B0588R
-
|
AL-4862 (Standard)
|
Carbonic Anhydrase
|
Others
Neurological Disease
|
|
Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
|
-
- HY-16726R
-
|
|
COX
Carbonic Anhydrase
|
Cancer
|
|
Polmacoxib (Standard) is the analytical standard of Polmacoxib. This product is intended for research and analytical applications. Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .
|
-
- HY-146988
-
|
|
Carbonic Anhydrase
Apoptosis
|
Cancer
|
|
hCAIX/XII-IN-1 is a potent CAIX/XII inhibitor with the KI values of 0.48 µM and 0.83 µM for CAIX and CAXII, respectively. hCAIX/XII-IN-1 shows antiproliferative activity in vitro. hCAIX/XII-IN-1 induces apoptosis in MCF-7 cells .
|
-
- HY-110234
-
|
McN 4853 D12 ; RWJ 17021 D12
|
iGluR
GABA Receptor
Sodium Channel
Calcium Channel
Potassium Channel
Carbonic Anhydrase
|
Neurological Disease
|
|
Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
|
-
- HY-N0639
-
|
|
HBV
Pyroptosis
Carbonic Anhydrase
|
Infection
Inflammation/Immunology
|
|
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
|
-
- HY-B0746
-
|
dl-Flurbiprofen sodium
|
Others
|
Inflammation/Immunology
|
|
Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
|
-
- HY-150695
-
|
|
Carbonic Anhydrase
Apoptosis
|
Cancer
|
|
hCAIX/XII-IN-5 (Coumarin 9a) a carbonic anhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis .
|
-
- HY-B0122R
-
|
|
iGluR
GABA Receptor
Sodium Channel
Calcium Channel
Potassium Channel
Carbonic Anhydrase
|
Neurological Disease
|
|
Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
|
-
- HY-B1471R
-
|
|
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
Fluorometholone acetate (Standard) is the analytical standard of Fluorometholone acetate. This product is intended for research and analytical applications. Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
|
-
- HY-149012
-
-
- HY-13650
-
Indisulam
Maximum Cited Publications
10 Publications Verification
E 7070
|
Molecular Glues
Carbonic Anhydrase
|
Cancer
|
|
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .
|
-
- HY-151578
-
|
|
Dipeptidyl Peptidase
Carbonic Anhydrase
|
Metabolic Disease
|
|
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .
|
-
- HY-155694
-
|
|
Carbonic Anhydrase
VEGFR
|
Cancer
|
|
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual Carbonic Anhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity .
|
-
- HY-156181
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonic anhydrase) CA IX and XII inhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II .
|
-
- HY-125575
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
FC11409B is an ureido-sulfamate carbonic anhydrase IX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O2) and normoxic conditions (21% O2). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers .
|
-
- HY-B0124
-
|
AD 810; CI 912
|
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
- HY-B0124A
-
|
AD 810 sodium; CI 912 sodium
|
Carbonic Anhydrase
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
- HY-110243
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .
|
-
- HY-155522
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines .
|
-
- HY-162521
-
|
|
Bacterial
Fungal
|
Infection
|
|
Antibacterial agent 215 (Compound 3b) is an inhibitor for carbonic anhydrase (CA), with Ki of 17.61, 5.14 and 43.74 nM, for hCA I, hCA II and AChE, respectively. Antibacterial agent 215 exhibits anti-tuberculosis, with MIC of 62.5 µg/ml against M. tuberculosis. Antibacterial agent 215 exhibits antifungal activities against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with MICs of 125 µg/ml .
|
-
- HY-W074975R
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CL 5343 (Standard) is the analytical standard of CL 5343. This product is intended for research and analytical applications. CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonic anhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .
|
-
- HY-76779
-
|
|
Others
|
Cancer
|
|
4-(Chloromethyl)-7-hydroxycoumarin (compound 4) is a hydroxycoumarin derivative with potent antioxidant effect and high hydroxyl radical-scavenging property. 4-(Chloromethyl)-7-hydroxycoumarin contains a methyl group and a chlorine group in the heterocyclic ring. A series of coumarins incorporating hydroxy-, chloro- and/or chloromethyl-moieties has been investigated as potent inhibitors of the zinc enzyme carbonic anhydrase, expecially tumor-associated isoforms CA IX and XII .
|
-
- HY-N0639R
-
|
|
HBV
Pyroptosis
Carbonic Anhydrase
|
Infection
Inflammation/Immunology
|
|
Punicalin (Standard) is the analytical standard of Punicalin. This product is intended for research and analytical applications. Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
|
-
- HY-147925
-
|
|
Carbonic Anhydrase
|
Others
|
|
hCAI/II-IN-4 (compound 6d) is a potent dual hCA I/II inhibitor with Ki values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research .
|
-
- HY-148135
-
|
|
Carbonic Anhydrase
|
Neurological Disease
|
|
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
|
-
- HY-162000
-
|
|
Apoptosis
|
Cancer
|
hCAIX/XII-IN-13 is an inhibitor of human carbonic anhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
|
-
- HY-B0122S
-
-
- HY-110234R
-
|
|
iGluR
GABA Receptor
Sodium Channel
Calcium Channel
Potassium Channel
Carbonic Anhydrase
|
Neurological Disease
|
|
Topiramate D12 (Standard) is the analytical standard of Topiramate D12. This product is intended for research and analytical applications. Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
|
-
- HY-168030
-
|
|
Apoptosis
Ferroptosis
Carbonic Anhydrase
Reactive Oxygen Species
Caspase
Mitochondrial Metabolism
|
Cancer
|
|
hCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research .
|
-
- HY-161522
-
|
|
Glucosidase
Carbonic Anhydrase
|
Endocrinology
|
|
α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective. .
|
-
- HY-B0124R
-
|
|
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
- HY-134043
-
|
Chlorthalidone EP Impurity G
|
Carbonic Anhydrase
|
Cardiovascular Disease
|
|
Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
|
-
- HY-113658
-
|
|
Others
|
Others
|
|
ts-SA is a carbonic anhydrase (CA) inhibitor with activity against seven human CA homologues. ts-SA can bind to the Zn(II) ion in the enzyme active site in a deprotonated form. The organic skeleton of ts-SA extends in the enzyme cavity and participates in multiple interactions with amino acid residues and water molecules. Due to its structural differences, the inhibitory performance of ts-SA is significantly better than that of another pyridine derivative. ts-SA exhibits low nanomolar inhibitory activity and is a multi-target CA inhibitor .
|
-
- HY-163691
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Antitumor agent-163 (Compound 3) is a photosensitizer used in Molecular-Targeted Photodynamic Therapy (MT-PDT) targeting carbonic anhydrase IX (CAIX). Antitumor agent-163 inactivates CAIX protein via singlet oxygen under 540 nm wavelength light, without affecting internal standard proteins such as α-tubulin, β-actin, and proliferating cell nuclear antigen (PCNA). Antitumor agent-163 induces cell membrane damage, inhibits cell viability (IC50 is 0.2 and 0.05 μM for A549 and U87MG). Antitumor agent-163 exhibits antitumor efficacy in mouse model .
|
-
- HY-146979
-
|
|
Adenosine Receptor
Carbonic Anhydrase
|
Cancer
|
|
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
|
-
- HY-159122
-
|
|
Carbonic Anhydrase
Reactive Oxygen Species
Apoptosis
|
Cancer
|
|
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonic anhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC50 of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC50s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D2345
-
|
|
Fluorescent Dyes/Probes
|
|
GZ22-4 is a near-infrared (NIR) fluorescent probe. GZ22-4 shows high affinity for carbonic anhydrase IX (CAIX), with a Kd of 0.2 nM. GZ22-4 can be used for the research of visualize CAIX-positive tumors .
|
| Cat. No. |
Product Name |
Type |
-
- HY-155887
-
|
DSPE-PEG-NH2, MW 3400 ammonium
|
Drug Delivery
|
|
DSPE-PEG-Amine, MW 3400 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 3400 (ammonium) can be converted to aromatic aldehydes by reacting with acetone-protected aromatic hydrazines on the surface of bovine carbonic anhydrase (BCA) molecules. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-155908
-
|
DSPE-PEG-NH2, MW 10000 ammonium
|
Drug Delivery
|
|
DSPE-PEG-Amine, MW 10000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 10000 (ammonium) can be converted into aromatic aldehydes by reacting with acetone-protected aromatic hydrazines on the surface of bovine carbonic anhydrase (BCA) molecules. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-155907
-
|
DSPE-PEG-NH2, MW 5000 ammonium
|
Drug Delivery
|
|
DSPE-PEG-Amine, MW 5000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. DSPE-PEG-Amine, MW 5000 (ammonium) amino group can be converted to aromatic aldehydes that react with acetone-protected aromatic hydrazides on the surface of the bovine carbonic anhydrase (BCA) molecule. Liposomes produce liposome-Bah-BCA conjugates by forming diaryl hydrazone (BAH) with target enzyme molecules. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-W440823A
-
|
DSPE-PEG-NH2, MW 1000 ammonium
|
Drug Delivery
|
|
DSPE-PEG-Amine, MW 1000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 1000 (ammonium) can be converted to an aromatic aldehyde, which reacts with an acetone-protected aromatic hydrazine on the surface of the bovine carbonic anhydrase (BCA) molecule. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99023
-
|
G250; cG250
|
Carbonic Anhydrase
|
Cancer
|
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0782S
-
|
|
|
Acetazolamide-d3 is deuterium labeled Acetazolamide, which is a potent carbonic anhydrase (CA) inhibitor.
|
-
-
- HY-B0124S
-
|
|
|
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
|
-
-
- HY-B0553S
-
|
|
|
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].
|
-
-
- HY-108316S
-
|
|
|
Sulthiame-d4 is the deuterium labeled Sultiame. Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent[1][2].
|
-
-
- HY-B0588S
-
|
|
|
Brinzolamide-d5 is the deuterium labeled Brinzolamide. Brinzolamide (AL 4862) is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.
|
-
-
- HY-B0782S1
-
|
|
|
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX[1]. Diuretic effects[4].
|
-
-
- HY-B0109S
-
|
|
|
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
|
-
-
- HY-B0109AS
-
|
|
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
|
-
-
- HY-B0588AS
-
|
|
|
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
|
-
-
- HY-B0122S
-
|
|
|
Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-159129
-
|
|
|
Azide
|
|
hCAXII-IN-10 (Compound 18b) is a dual inhibitor of human carbonic anhydrase isoform XII (hCAXII) and cathepsin B, with a Ki value of 2.2 nM. hCAXII-IN-10 can inhibit the role of hCAXII in providing tumors with a pH microenvironment conducive to tumor growth, and is expected to be used in the study of tumor diseases .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-155887
-
|
DSPE-PEG-NH2, MW 3400 ammonium
|
|
Pegylated Lipids
|
|
DSPE-PEG-Amine, MW 3400 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 3400 (ammonium) can be converted to aromatic aldehydes by reacting with acetone-protected aromatic hydrazines on the surface of bovine carbonic anhydrase (BCA) molecules. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-155908
-
|
DSPE-PEG-NH2, MW 10000 ammonium
|
|
Pegylated Lipids
|
|
DSPE-PEG-Amine, MW 10000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 10000 (ammonium) can be converted into aromatic aldehydes by reacting with acetone-protected aromatic hydrazines on the surface of bovine carbonic anhydrase (BCA) molecules. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-155907
-
|
DSPE-PEG-NH2, MW 5000 ammonium
|
|
Pegylated Lipids
|
|
DSPE-PEG-Amine, MW 5000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. DSPE-PEG-Amine, MW 5000 (ammonium) amino group can be converted to aromatic aldehydes that react with acetone-protected aromatic hydrazides on the surface of the bovine carbonic anhydrase (BCA) molecule. Liposomes produce liposome-Bah-BCA conjugates by forming diaryl hydrazone (BAH) with target enzyme molecules. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
-
- HY-W440823A
-
|
DSPE-PEG-NH2, MW 1000 ammonium
|
|
Pegylated Lipids
|
|
DSPE-PEG-Amine, MW 1000 (ammonium) is a phosphoethanolamine involved in the synthesis of liposomes for delivery systems. The amino group of DSPE-PEG-Amine, MW 1000 (ammonium) can be converted to an aromatic aldehyde, which reacts with an acetone-protected aromatic hydrazine on the surface of the bovine carbonic anhydrase (BCA) molecule. Liposomes form a liposome-BAH-BCA conjugate by forming a bisarylhydrazone (BAH) with the target enzyme molecule. The conjugate catalyzes the hydration of carbon dioxide to bicarbonate.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
